Michael Nagle | Bloomberg | Getty Images
Pedestrians walk past a Walgreens store in New York.
Walgreens Boots Alliance on Tuesday reported quarterly earnings and revenue that missed analysts' expectations.
The drugstore chain also lowered its full-year earnings forecast to be roughly flat, compared with its previous forecast of 7 percent to 12 percent growth. The company's shares slid 7 percent in premarket trading.
Walgreens reported adjusted earnings of $1.64 per share, missing analysts polled by Refinitiv's expectations of $1.72 per share. Revenue also fell short, coming in at $34.53 billion. Analysts had been looking for $34.56 billion.
Walgreens reported fiscal second-quarter net income of $1.16 billion, or $1.24 per share, down from $1.35 billion, or $1.36 per share a year earlier.
On an adjusted basis, Walgreens earned $1.64 per share, below the $1.72 billion analysts had expected. Net sales rose 4.6 percent to $34.53 billion, below expectations of $34.56 billion.
Executives from Walgreens and rival CVS Health have warned investors in recent months that profits might not be all that fat this year. The Trump administration has been pressuring drugmakers and pharmacy benefits managers to lower consumer prices, both of which may cut into the bottom line for drugstore chains.
Drugstores are trying to diversify their products and experiment with new ways to get people into their stores. Walgreens last week said it will sell CBD products in about 1,500 of its stores, following CVS.
Walgreens is working with LabCorp, Humana, Sprint and others on everything from offering senior care services to selling phones in their stores. CVS is changing up its business model after buying health insurer Aetna for $70 billion late last year.
